Pseudomyxoma peritonei natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
==Prognosis== | ==Prognosis== | ||
*Although PMP as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a morbid, recurrent condition with life-threatening complications. | |||
*Biological features of the tumor and access to the current standard of care at specialized oncology centers with a peritoneal surface malignancy program comprise the most important prognostic determinants of PMP. | |||
*Through a retrospective, multi-institutional study on 2298 patients treated at 16 specialized centers affiliated with the Peritoneal Surface Oncology Group International, Chua et al. reported a median survival rate of 196 months (16.3 years) and a median progression-free survival rate of 98 months (8.2 years) as well as 10- and 15-year survival rates of 63% and 59%, respectively. | |||
==References== | ==References== | ||
Revision as of 16:43, 25 November 2015
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei natural history, complications and prognosis |
|
FDA on Pseudomyxoma peritonei natural history, complications and prognosis |
|
CDC on Pseudomyxoma peritonei natural history, complications and prognosis |
|
Pseudomyxoma peritonei natural history, complications and prognosis in the news |
|
Blogs on Pseudomyxoma peritonei natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Natural History
Complications
Prognosis
- Although PMP as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a morbid, recurrent condition with life-threatening complications.
- Biological features of the tumor and access to the current standard of care at specialized oncology centers with a peritoneal surface malignancy program comprise the most important prognostic determinants of PMP.
- Through a retrospective, multi-institutional study on 2298 patients treated at 16 specialized centers affiliated with the Peritoneal Surface Oncology Group International, Chua et al. reported a median survival rate of 196 months (16.3 years) and a median progression-free survival rate of 98 months (8.2 years) as well as 10- and 15-year survival rates of 63% and 59%, respectively.